2024 was a groundbreaking year for oncology and rare diseases treatments, with the FDA approving multiple novel and pathbreaking therapies.
In this CMO Confidential video, Precision’s Chief Medical Officer and former FDA Oncology Division Director, Harpreet Singh, MD, highlights the top three approvals that will shape oncology innovation in 2025.
Access this on-demand video to discover key insights on the transformations, set to define the year ahead.
Offered Free by: Precision for Medicine
See All Resources from: Precision for Medicine
